From Inquiry to Investigation to Insight:
Clinical Clarity in Non-Small Cell Lung Cancer

A comprehensive update on recent advances in evidence-based care for patients with non–small cell lung cancer. This activity includes expert perspectives on options for testing, managing disease in the early stages to metastatic stages, the advent of immunotherapy and targeted therapy, and how to manage the potential adverse events of these novel agents.

Click on any of the video presentations below to get started!

All  |  NSCLC

Disease Overview Followed by Selecting Treatments Using Biomarker Testing and Molecular Profiling

Review of strategies for planning therapy based on results of biomarker tests, liquid biopsies, as well as next-generation sequencing and tumor mutational burden profiles.

Posted: December 10, 2019 / Expires: December 10, 2020

Estimated time to complete: 0.75

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


Managing Early-Stage and Locally Advanced NSCLC

Discussion of evidence-based management of disease using a multimodal approach that includes surgery, adjuvant chemotherapy, chemoradiation, and immunotherapy.

Posted: December 10, 2019 / Expires: December 10, 2020

Estimated time to complete: 0.75

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


The Role of Immune Checkpoint Inhibitors With and Without Combination Therapy for Nonmutated Metastatic NSCLC

Analysis of therapeutic approaches using immune checkpoint inhibitors alone or with other agents in first-line setting and beyond.

Posted: December 10, 2019 / Expires: December 10, 2020

Estimated time to complete: 1.0

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


Managing Immune-Related Adverse Events

Review of clinical and patient education strategies for identifying, mitigating, and addressing adverse events associated with immune checkpoint inhibitors.        

Posted: December 10, 2019 / Expires: December 10, 2020

Estimated time to complete: 0.75

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


Managing EGFR+ Metastatic NSCLC

Overview of the rationale for targeting EGFR-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of EGFR inhibitors in the first-line setting and beyond.

Posted: December 10, 2019 / Expires: December 10, 2020

Estimated time to complete: 0.5

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


Managing ALK+ and ROS1+ Metastatic NSCLC

Description Overview of the rationale for targeting ALK- and ROS1-mutated NSCLC, followed by an evaluation of clinical data and best practices supporting the safe and effective use of ALK inhibitors in the first-line setting and beyond.

Posted: December 10, 2019 / Expires: December 10, 2020

Estimated time to complete: 0.50

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


Managing Patients With Other Mutations in Metastatic NSCLC and Upcoming Clinical Trials

Evaluation of the rationale for and clinical data supporting targeting driver mutations in NSCLC, such as BRAF, KRAS, and RET. Appraisal of clinical trials planned or in progress in lung cancer for which preliminary or updated data release has occurred in the past 12 months or is expected in the next 6 months. Discussion of new approvals for small cell lung cancer.

Posted: December 10, 2019 / Expires: December 10, 2020

Estimated time to complete: 0.75

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


Identifying and Avoiding Drug Interactions

Discussion of best practices for mitigating drug-drug interactions and drug-disease interactions.

Posted: December 10, 2019 / Expires: December 10, 2020

Estimated time to complete: 0.50

Access the Activity for CE Credit*
   
Watch Video Without Claiming Credit

* This link will take you to the Annenberg
Center for Health Sciences website.


Non-Certified Video


Consult the Experts: Case Challenges From Conference Participants

Discussion of clinical decision points involved in challenging patient cases, with a focus on how patient disease characteristics and personal preferences can be used to guide clinical decision-making.

Watch Video Without Claiming Credit

 
These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.